BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
BBOT ended the second quarter with $344.1 million in cash and marketable securities, providing a runway expected to fund operations into 2028. The company advanced its clinical pipeline, initiating dosing of BBO-11818 in combination with cetuximab and BBO-10203, while presenting positive preclinical data for its RAS-pathway inhibitors at AACR.
Key figures
- Net loss
- $56.5 million
- Cash runway
- into 2028
- Ga expenses
- $11.0 million
- Rd expenses
- $49.2 million
- Cash and securities
- $344.1 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.